Literature DB >> 8995720

Up-regulation of tubular epithelial interleukin-12 in autoimmune MRL-Fas(lpr) mice with renal injury.

X Fan1, B Oertli, R P Wüthrich.   

Abstract

Phagocyte-derived interleukin-12 (IL-12) is a key cytokine that induces the development of an effective Th1 type immune response in various inflammatory and infectious disorders. To determine the importance of IL-12 in the pathogenesis of autoimmune renal injury we examined the renal production of this heterodimeric cytokine in the MRL-Fas(lpr) lupus nephritis model. Compared with normal mice RT-PCR products encoding both the p35 and p40 subunits of IL-12 were markedly increased in the kidney of MRL-Fas(lpr). Immunofluorescence staining demonstrated expression of the IL-12 p75 heterodimer on isolated infiltrating mononuclear cells and also on proximal tubular epithelial cells in MRL-Fas(lpr) but less in normal mice kidneys. The enhanced expression of IL-12 correlated with an increased intrarenal transcription of IFN-gamma. The p35 and p40 transcripts and soluble IL-12 p75 protein were also produced by cultured TEC. In addition, membrane bound IL-12 was detected on Tec. We conclude that IL-12 production is significantly up-regulated in MRL-Fas(lpr) lupus nephritis. In addition to mononuclear cells, TEC are an important source of IL-12 and could thereby participate in the development of a Th1 type immune response in autoimmune renal injury.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995720     DOI: 10.1038/ki.1997.10

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  16 in total

Review 1.  Tumour necrosis factor and other cytokines in murine lupus.

Authors:  A N Theofilopoulos; B R Lawson
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Calorie restriction decreases proinflammatory cytokines and polymeric Ig receptor expression in the submandibular glands of autoimmune prone (NZB x NZW)F1 mice.

Authors:  A R Muthukumar; C A Jolly; K Zaman; G Fernandes
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

3.  Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice.

Authors:  Julia Menke; Tillmann Bork; Birte Kutska; Katelyn T Byrne; Michaela Blanfeld; Manfred Relle; Vicki R Kelley; Andreas Schwarting
Journal:  Kidney Int       Date:  2010-10-27       Impact factor: 10.612

4.  Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus.

Authors:  J P Mackern-Oberti; J Obreque; G P Méndez; C Llanos; A M Kalergis
Journal:  Clin Exp Immunol       Date:  2015-07-07       Impact factor: 4.330

5.  The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice.

Authors:  Y Nozaki; T Yamagata; B-S Yoo; M Sugiyama; S Ikoma; K Kinoshita; M Funauchi; A Kanamaru
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

6.  Augmentation of natural killer cell activity in mice by oral administration of transforming growth factor-beta.

Authors:  S Ishizaka; M Kimoto; S Kanda; S Saito
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

Review 7.  Cytokine overproduction, T-cell activation, and defective T-regulatory functions promote nephritis in systemic lupus erythematosus.

Authors:  Marco Tucci; Stefania Stucci; Sabino Strippoli; Francesco Silvestris
Journal:  J Biomed Biotechnol       Date:  2010-06-29

Review 8.  The multi-faceted influences of estrogen on lymphocytes: toward novel immuno-interventions strategies for autoimmunity management.

Authors:  Ebru Karpuzoglu; Moncef Zouali
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

Review 9.  Cytokines in systemic lupus erythematosus.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Curr Mol Med       Date:  2009-04       Impact factor: 2.222

10.  STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk.

Authors:  A-K Abelson; A M Delgado-Vega; S V Kozyrev; E Sánchez; R Velázquez-Cruz; N Eriksson; J Wojcik; M V P Linga Reddy; G Lima; S D'Alfonso; S Migliaresi; V Baca; L Orozco; T Witte; N Ortego-Centeno; H Abderrahim; B A Pons-Estel; C Gutiérrez; A Suárez; M F González-Escribano; J Martin; M E Alarcón-Riquelme
Journal:  Ann Rheum Dis       Date:  2008-11-19       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.